WCLC 2025 - Posters & ePosters-P3.03.26 Ir-Metal Framework Loaded With Radiation-Responsive Anti-Angiogenic Prodrugs for Enhanced Radiotherapy Efficacy

P3.03.26 Ir-Metal Framework Loaded With Radiation-Responsive Anti-Angiogenic Prodrugs for Enhanced Radiotherapy Efficacy

Back to course

Pdf Summary

This study by Qin Zhang from Shanghai Jiao Tong University introduces an innovative Iridium metal framework (Ir-MF) system loaded with radiation-responsive anti-angiogenic prodrugs to improve radiotherapy outcomes, particularly in lung cancer treatment. Radiotherapy effectiveness is often limited by tumor hypoxia and abnormal angiogenesis, which promote radioresistance. To overcome this, the researchers designed an Ir-MF@PP system combining an iridium metal framework with a pazopanib prodrug and SH-PEG-NH2. The Ir-MF acts as both a drug carrier and a radiosensitizer, while the pazopanib prodrug is a multi-targeted tyrosine kinase inhibitor targeting VEGF to normalize tumor vasculature. <br /><br />Upon radiotherapy, Ir-MF generates reactive oxygen species (ROS), enhancing tumor cell sensitivity and allowing effective treatment at reduced radiation doses, minimizing harm to healthy tissue. Concurrently, radiation triggers the controlled release of pazopanib, improving vascular normalization, enhancing blood perfusion, and alleviating tumor hypoxia. This dual-action approach increases local drug concentration and safety, addressing key resistance mechanisms in tumors.<br /><br />Efficacy of the Ir-MF@PP system was confirmed at both cellular and animal model levels, demonstrating enhanced radiosensitization and improved tumor control. By directly sensitizing tumor cells and indirectly promoting vascular normalization, this strategy offers superior tumor killing effects and represents a promising avenue for more precise, effective lung cancer radiotherapy.

Asset Subtitle

Qin Zhang

Meta Tag

Speaker Qin Zhang

Topic Tumor Biology – Translational Biology

Keywords

Iridium metal framework

Ir-MF@PP system

radiotherapy

lung cancer

tumor hypoxia

angiogenesis

pazopanib prodrug

radiosensitizer

reactive oxygen species

vascular normalization